Oligonucleotides and G-quadruplex stabilizers: Targeting telomeres and telomerase in cancer therapy

Current Pharmaceutical Design

Volumn 20, Issue 41, 2014, Pages 6422-6437

  Crees, Zachary ^a   Girard, Jennifer ^a   Rios, Zechary ^a   Botting, Gregory M ^a   Harrington, Kymberly ^a   Shearrow, Caleb ^a   Wojdyla, Luke ^a   Stone, Amanda L ^a   Uppada, Srijayaprakash B ^a   Devito, Joseph T ^a   Puri, Neelu ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Clinical trials; G quadruplex; GRN163L; T oligo; Tankyrase; Telomerase; Telomerase inhibitor; Telomere

Indexed keywords

ATM PROTEIN; BEVACIZUMAB; BRACO 19; DOXORUBICIN; GEMCITABINE; GUANINE QUADRUPLEX; IMETELSTAT; OLIGONUCLEOTIDE; PACLITAXEL; POT1 PROTEIN; PROTEIN; PROTEIN P53; RAP1 PROTEIN; REPLICATION FACTOR A; RHPS4; RITONAVIR; SHELTERIN; SINGLE STRANDED DNA; STABILIZING AGENT; TANKYRASE; TANKYRASE 1; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; TELOMESTATIN; TIN2 PROTEIN; TPP1 PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WERNER SYNDROME PROTEIN; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CELL AGING; CELL CYCLE S PHASE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; DNA DAMAGE; DNA DENATURATION; DNA REPLICATION; ESOPHAGEAL ADENOCARCINOMA; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; MYELOFIBROSIS; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL INTESTINE CANCER; SOLID TUMOR; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; THROMBOCYTHEMIA; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; TELOMERE;

ANIMALS; ANTINEOPLASTIC AGENTS; G-QUADRUPLEXES; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES; TELOMERASE; TELOMERE;

EID: 84911490392     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140630100702     Document Type: Article

References (200)

1. Wang F, Podell ER, Zaug AJ, et al. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature 2007; 445: 506-10.
2. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19: 2100-10.
3. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661-73.
4. Zaug AJ, Podell ER, Cech TR. Human POT1 disrupts telomeric G-quadruplexes allowing telomerase extension in vitro. Proc Natl Acad Sci USA 2005; 102: 10864-9.
5. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114: 241-53.
6. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008; 8: 450-8.
7. Hao YH, Tan Z. The generation of long telomere overhangs in human cells: a model and its implication. Bioinformatics 2002; 18: 666-71.
8. Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol 2011; 21: 349-53.
9. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
10. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001; 10: 677-85.
11. Riethman H. Human telomere structure and biology. Annu Rev Genomics Hum Genet 2008; 9: 1-19.
12. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001; 11: S27-31.
13. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
14. Xu L, Li S, Stohr BA. The role of telomere biology in cancer. Annu Rev Pathol 2013; 8: 49-78.
15. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013; 39: 444-56.
16. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008; 98: 677-83.
17. Agrawal A, Dang S, Gabrani R. Recent patents on anti-telomerase cancer therapy. Recent Pat Anticancer Drug Discov 2012; 7: 102-17.
18. Dikmen ZG, Wright WE, Shay JW, Gryaznov SM. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells. J Cell Biochem 2008; 104: 444-52.
19. Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)--telomerase-based cancer therapy. Recent Results Cancer Res 2010; 184: 221-34.
20. Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. Br J Pharmacol 2007; 152: 1003-11.
21. Neidle S. Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer. FEBS J 2010; 277: 1118-25.
22. De Cian A, Lacroix L, Douarre C, et al. Targeting telomeres and telomerase. Biochimie 2008; 90: 131-55.
23. Neidle S, Parkinson G. Telomere maintenance as a target for anticancer drug discovery. Nat Rev Drug Discov 2002; 1: 383-93.
24. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8: 167-79.
25. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998; 282: 1484-7.
26. Pitman RT, Wojdyla L, Puri N. Mechanism of DNA damage responses induced by exposure to an oligonucleotide homologous to the telomere overhang in melanoma. Oncotarget 2013; 4: 761-71.
27. De Rycker M, Price CM. Tankyrase polymerization is controlled by its sterile alpha motif and poly(ADP-ribose) polymerase domains. Mol Cell Biol 2004; 24: 9802-12.
28. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-20.
29. McCabe N, Cerone MA, Ohishi T, et al. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 2009; 28: 1465-70.
30. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 2005; 7: 25-37.
31. Sarkar S, Faller DV. T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides 2011; 21: 47-53.
32. Puri N, Eller MS, Byers HR, et al. Telomere-based DNA damage responses: a new approach to melanoma. FASEB J 2004; 18: 1373-81.
33. Longe HO, Romesser PB, Rankin AM, et al. Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer 2009; 124: 473-82.
34. Puri N, Pitman RT, Mulnix RE, et al. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett 2013.
35. Rankin AM, Faller DV, Spanjaard RA. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs 2008; 19: 329-38.
36. Rankin AM, Sarkar S, Faller DV. Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J Cell Physiol 2012; 227: 2586-94.
37. Yaar M, Eller MS, Panova I, et al. Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res 2007; 9: R13.
38. O'Connor MS, Safari A, Xin H, Liu D, Songyang Z. A critical role for TPP1 and TIN2 interaction in high-order telomeric complex assembly. Proc Natl Acad Sci USA 2006; 103: 11874-9.
39. Smith S, de Lange T. TRF1, a mammalian telomeric protein. Trends Genet 1997; 13: 21-6.
40. Ye JZ, Hockemeyer D, Krutchinsky AN, et al. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev 2004; 18: 1649-54.
41. Baumann P, Cech TR. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 2001; 292: 1171-5.
42. Blackburn EH. Telomere states and cell fates. Nature 2000; 408: 53-6.
43. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999; 283: 1321-5.
44. Etheridge KT, Compton SA, Barrientos KS, et al. Tethering telomeric double-and single-stranded DNA-binding proteins inhibits telomere elongation. J Biol Chem 2008; 283: 6935-41.
45. Karlseder J, Hoke K, Mirzoeva OK, et al. The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response. PLoS Biol 2004; 2: E240.
46. Fujita K, Horikawa I, Mondal AM, et al. Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol 2010; 12: 1205-12.
47. Horikawa I, Fujita K, Harris CC. p53 governs telomere regulation feedback too, via TRF2. Aging (Albany NY) 2011; 3: 26-32.
48. Martinez P, Thanasoula M, Carlos AR, et al. Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. Nat Cell Biol 2010; 12: 768-80.
49. Sfeir A, Kabir S, van Overbeek M, Celli GB, de Lange T. Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science 2010; 327: 1657-61.
50. Li B, Oestreich S, de Lange T. Identification of human Rap1: implications for telomere evolution. Cell 2000; 101: 471-83.
51. Kim SH, Beausejour C, Davalos AR, et al. TIN2 mediates functions of TRF2 at human telomeres. J Biol Chem 2004; 279: 43799-804.
52. Wang H, Nora GJ, Ghodke H, Opresko PL. Single molecule studies of physiologically relevant telomeric tails reveal POT1 mechanism for promoting G-quadruplex unfolding. J Biol Chem 2011; 286: 7479-89.
53. Takai KK, Kibe T, Donigian JR, Frescas D, de Lange T. Telomere protection by TPP1/POT1 requires tethering to TIN2. Mol Cell 2011; 44: 647-59.
54. Tian X, Chen B, Liu X. Telomere and telomerase as targets for cancer therapy. Appl Biochem Biotechnol 2010; 160: 1460-72.
55. Kim SH, Davalos AR, Heo SJ, et al. Telomere dysfunction and cell survival: roles for distinct TIN2-containing complexes. J Cell Biol 2008; 181: 447-60.
56. Ha GH, Kim HS, Go H, et al. Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation. Cell Death Differ 2012; 19: 321-32.
57. Biffi G, Tannahill D, Balasubramanian S. An intramolecular G-quadruplex structure is required for binding of telomeric repeat-containing RNA to the telomeric protein TRF2. J Am Chem Soc 2012; 134: 11974-6.
58. Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 2007; 318: 798-801.
59. Deng Z, Norseen J, Wiedmer A, Riethman H, Lieberman PM. TERRA RNA binding to TRF2 facilitates heterochromatin formation and ORC recruitment at telomeres. Mol Cell 2009; 35: 403-13.
60. Schoeftner S, Blasco MA. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nat Cell Biol 2008; 10: 228-36.
61. Diehl MC, Idowu MO, Kimmelshue KN, et al. Elevated TRF2 in advanced breast cancers with short telomeres. Breast Cancer Res Treat 2011; 127: 623-30.
62. Takai KK, Hooper S, Blackwood S, Gandhi R, de Lange T. In vivo stoichiometry of shelterin components. J Biol Chem 2010; 285: 1457-67.
63. Corriveau M, Mullins MR, Baus D, Harris ME, Taylor DJ. Coordinated interactions of multiple POT1-TPP1 proteins with telomere DNA. J Biol Chem 2013; 288: 16361-70.
64. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-9.
65. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785-95.
66. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995; 269: 1236-41.
67. Harrington L, McPhail T, Mar V, et al. A mammalian telomerase-associated protein. Science 1997; 275: 973-7.
68. Wu KJ, Grandori C, Amacker M, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220-4.
69. Blackburn EH. Telomerase and Cancer: Kirk A. Landon--AACR prize for basic cancer research lecture. Mol Cancer Res 2005; 3: 477-82.
70. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005; 11: 217-25.
71. Bechter OE, Zou Y, Walker W, Wright WE, Shay JW. Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res 2004; 64: 3444-51.
72. de Lange T, Shiue L, Myers RM, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990; 10: 518-27.
73. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11: 1921-9.
74. Cesare AJ, Griffith JD. Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol 2004; 24: 9948-57.
75. Chung I, Osterwald S, Deeg KI, Rippe K. PML body meets telomere: the beginning of an ALTernate ending? Nucleus 2012; 3: 263-75.
76. Schaffitzel C, Berger I, Postberg J, et al. In vitro generated antibodies specific for telomeric guanine-quadruplex DNA react with Stylonychia lemnae macronuclei. Proc Natl Acad Sci USA 2001; 98: 8572-7.
77. Maizels N. Dynamic roles for G4 DNA in the biology of eukaryotic cells. Nat Struct Mol Biol 2006; 13: 1055-9.
78. Sampathi S, Chai W. Telomere replication: poised but puzzling. J Cell Mol Med 2011; 15: 3-13.
79. Damerla RR, Knickelbein KE, Strutt S, et al. Werner syndrome protein suppresses the formation of large deletions during the replication of human telomeric sequences. Cell Cycle 2012; 11: 3036-44.
80. Fry M, Loeb LA. Human werner syndrome DNA helicase unwinds tetrahelical structures of the fragile X syndrome repeat sequence d(CGG)n. J Biol Chem 1999; 274: 12797-802.
81. Sun H, Karow JK, Hickson ID, Maizels N. The Bloom's syndrome helicase unwinds G4 DNA. J Biol Chem 1998; 273: 27587-92.
82. Mohaghegh P, Karow JK, Brosh RM, Jr., Bohr VA, Hickson ID. The Bloom's and Werner's syndrome proteins are DNA structure-specific helicases. Nucleic Acids Res 2001; 29: 2843-9.
83. Sarkies P, Murat P, Phillips LG, et al. FANCJ coordinates two pathways that maintain epigenetic stability at G-quadruplex DNA. Nucleic Acids Res 2012; 40: 1485-98.
84. Opresko PL, Otterlei M, Graakjaer J, et al. The Werner syndrome helicase and exonuclease cooperate to resolve telomeric D loops in a manner regulated by TRF1 and TRF2. Mol Cell 2004; 14: 763-74.
85. Crabbe L, Verdun RE, Haggblom CI, Karlseder J. Defective telomere lagging strand synthesis in cells lacking WRN helicase activity. Science 2004; 306: 1951-3.
86. Arnoult N, Saintome C, Ourliac-Garnier I, Riou JF, Londono-Vallejo A. Human POT1 is required for efficient telomere C-rich strand replication in the absence of WRN. Genes Dev 2009; 23: 2915-24.
87. Qureshi MH, Ray S, Sewell AL, Basu S, Balci H. Replication Protein A Unfolds G-Quadruplex Structures with Varying Degrees of Efficiency. J Phys Chem B 2012; 116: 5588-94.
88. Hwang H, Buncher N, Opresko PL, Myong S. POT1-TPP1 regulates telomeric overhang structural dynamics. Structure 2012; 20: 1872-80.
89. Yang D, Okamoto K. Structural insights into G-quadruplexes: towards new anticancer drugs. Future Med Chem 2010; 2: 619-46.
90. Shalaby T, Fiaschetti G, Nagasawa K, et al. G-quadruplexes as potential therapeutic targets for embryonal tumors. Molecules 2013; 18: 12500-37.
91. Vannier JB, Pavicic-Kaltenbrunner V, Petalcorin MI, Ding H, Boulton SJ. RTEL1 dismantles T loops and counteracts telomeric G4-DNA to maintain telomere integrity. Cell 2012; 149: 795-806.
92. Uringa EJ, Youds JL, Lisaingo K, Lansdorp PM, Boulton SJ. RTEL1: an essential helicase for telomere maintenance and the regulation of homologous recombination. Nucleic Acids Res 2011; 39: 1647-55.
93. Xu Y. Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA. Chem Soc Rev 2011; 40: 2719-40.
94. Eller MS, Puri N, Hadshiew IM, Venna SS, Gilchrest BA. Induction of apoptosis by telomere 3' overhang-specific DNA. Exp Cell Res 2002; 276: 185-93.
95. Bekaert S, De Meyer T, Van Oostveldt P. Telomere attrition as ageing biomarker. Anticancer Res 2005; 25: 3011-21.
96. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-52.
97. Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003; 63: 3931-9.
98. Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005; 65: 7866-73.
99. Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 2009; 6: 686-95.
100. Herbert BS, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005; 24: 5262-8.
101. Gryaznov SM. Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents. Chem Biodivers 2010; 7: 477-93.
102. Roh JI, Sung YH, Lee HW. Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer. Onco Targets Ther 2013; 6: 1161-6.
103. Gryaznov SM, Jackson S, Dikmen G, et al. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Nucleosides Nucleotides Nucleic Acids 2007; 26: 1577-9.
104. Herbert BS, Pongracz K, Shay JW, Gryaznov SM. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors. Oncogene 2002; 21: 638-42.
105. Gryaznov S, Pongracz K, Matray T, et al. Telomerase inhibitors--oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids 2001; 20: 401-10.
106. Gryaznov S, Asai A, Oshima Y, et al. Oligonucleotide N3'--> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents. Nucleosides Nucleotides Nucleic Acids 2003; 22: 577-81.
107. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 2006; 96: 73-81.
108. Tokcaer-Keskin Z, Dikmen ZG, Ayaloglu-Butun F, et al. The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6. Stem Cell Rev 2010; 6: 224-33.
109. Marian CO, Cho SK, McEllin BM, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010; 16: 154-63.
110. Hashizume R, Ozawa T, Gryaznov SM, et al. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008; 10: 112-20.
111. Jason TL, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004; 201: 66-83.
112. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-93.
113. Hochreiter AE, Xiao H, Goldblatt EM, et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 2006; 12: 3184-92.
114. Brennan SK, Wang Q, Tressler R, et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 2010; 5: e12487.
115. Shammas MA, Koley H, Bertheau RC, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008; 22: 1410-8.
116. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-5.
117. Goldblatt EM, Gentry ER, Fox MJ, et al. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther 2009; 8: 2027-35.
118. Uziel O, Beery E, Dronichev V, et al. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. PLoS One 2010; 5: e9132.
119. Goldblatt EM, Erickson PA, Gentry ER, Gryaznov SM, Herbert BS. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer Res Treat 2009; 118: 21-32.
120. Shammas MA, Qazi A, Batchu RB, et al. Telomere maintenance in laser capture micro dissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res 2008; 14: 4971-80.
121. Wu X, Smavadati S, Nordfjall K, et al. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. Biochim Biophys Acta 2012; 1823: 2130-5.
122. Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013; 13: 727-38.
123. Joseph I, Tressler R, Bassett E, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010; 70: 9494-504.
124. Marian CO, Wright WE, Shay JW. The effects of telomerase inhibition on prostate tumor-initiating cells. Int J Cancer 2010; 127: 321-31.
125. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-36.
126. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
127. Ratain MJ, Heath E, Weise A, et al. Intermittent dosing of Imetelstat Sodium, a telomerase inhibitor, induces drug exposure consistent with in vivo tumor growth inhibition. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2009 Nov 15-19; Boston, MA.
128. Thompson PA, Drissi R, Muscal JA, et al. A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res 2013; 19: 6578-84.
129. Calado R, Young N. Telomeres in disease. F1000 Med Rep 2012; 4: 8.
130. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet 2012; 13: 693-704.
131. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012; 2012: 571-81.
132. NCT01243073. Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (ET/PV). Available at http://clinicaltrials. gov/show/NCT01243073 [accessed 21 December 2013].
133. Baerlocher GM, Leibundgut EO, Spitzer G, et al. Imetelstat: A Novel Approach with Robust Hematologic and Molecular Responses in a Phase II Study in Patients with Essential Thrombocythemia Who are Refractory or Intolerant to Prior Therapy. 18th Congress of the European Hematology Association; 2013 June 13-16; Stockholm, Sweden.
134. NCT00510445. Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer; Available at http://clinicaltrials. gov/show/NCT00510445. [Accessed 31 October 2013].
135. Chiappori A, Bassett K, Burington B, et al. Improved Progression Free Survival (PFS) in Patients with Short Tumor Telomere Length: Subgroup Analysis from a Randomized Phase II Study of the Telomerase Inhibitor Imetelstat as a Maintenance Therapy for Advanced NSCLC. AACR Annual Meeting 2013; 2013 April 9; Washington, DC.
136. Kozloff M, Sledge GW, Benedetti FM, et al. Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). 2010 ASCO Annual Meeting; 2010 June 4-8; Chicago, IL.
137. Tauchi T, Shin-ya K, Sashida G, et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 2006; 25: 5719-25.
138. Burger AM, Dai F, Schultes CM, et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res 2005; 65: 1489-96.
139. Gunaratnam M, Greciano O, Martins C, et al. Mechanism of acridine-based telomerase inhibition and telomere shortening. Biochem Pharmacol 2007; 74: 679-89.
140. Cookson JC, Dai F, Smith V, et al. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3, 11-difluoro-6, 8, 13-trimethyl-8H-quino[4, 3, 2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol Pharmacol 2005; 68: 1551-8.
141. Salvati E, Leonetti C, Rizzo A, et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest 2007; 117: 3236-47.
142. Chung WJ, Heddi B, Tera M, et al. Solution structure of an intramolecular (3 + 1) human telomeric G-quadruplex bound to a telomestatin derivative. J Am Chem Soc 2013; 135: 13495-501.
143. Lormand JD, Buncher N, Murphy CT, et al. DNA polymerase delta stalls on telomeric lagging strand templates independently from G-quadruplex formation. Nucleic Acids Res 2013; 41: 10323-33.
144. Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov 2011; 10: 261-75.
145. Salvati E, Scarsella M, Porru M, et al. PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene 2010; 29: 6280-93.
146. Rizzo A, Salvati E, Porru M, et al. Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Res 2009; 37: 5353-64.
147. Monchaud D, Teulade-Fichou MP. A hitchhiker's guide to G-quadruplex ligands. Org Biomol Chem 2008; 6: 627-36.
148. Kim MY, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc 2002; 124: 2098-9.
149. Monchaud D, Granzhan A, Saettel N, et al. "One ring to bind them all"-part I: the efficiency of the macrocyclic scaffold for g-quadruplex DNA recognition. J Nucleic Acids 2010; 2010: pii 525862.
150. Temime-Smaali N, Guittat L, Sidibe A, et al. The G-quadruplex ligand telomestatin impairs binding of topoisomerase IIIalpha to G-quadruplex-forming oligonucleotides and uncaps telomeres in ALT cells. PLoS One 2009; 4: e6919.
151. Gomez D, Wenner T, Brassart B, et al. Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells. J Biol Chem 2006; 281: 38721-9.
152. Miyazaki T, Pan Y, Joshi K, et al. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res 2012; 18: 1268-80.
153. Tahara H, Shin-Ya K, Seimiya H, et al. G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene 2006; 25: 1955-66.
154. Alcaro S, Costa G, Distinto S, et al. The polymorphisms of DNA G-quadruplex investigated by docking experiments with telomestatin enantiomers. Curr Pharm Des 2012; 18: 1873-9.
155. Doi T, Shibata K, Yoshida M, et al. (S)-stereoisomer of telomestatin as a potent G-quadruplex binder and telomerase inhibitor. Org Biomol Chem 2011; 9: 387-93.
156. Kelland LR. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects. Eur J Cancer 2005; 41: 971-9.
157. Gowan SM, Harrison JR, Patterson L, et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 2002; 61: 1154-62.
158. Taetz S, Baldes C, Murdter TE, et al. Biopharmaceutical characterization of the telomerase inhibitor BRACO19. Pharm Res 2006; 23: 1031-7.
159. Saini V, Hose CD, Monks A, et al. Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One 2012; 7: e41401.
160. Phatak P, Cookson JC, Dai F, et al. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer 2007; 96: 1223-33.
161. Leonetti C, Scarsella M, Riggio G, et al. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin Cancer Res 2008; 14: 7284-91.
162. Gunaratnam M, Green C, Moreira JB, et al. G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo. Biochem Pharmacol 2009; 78: 115-22.
163. Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin. Ann N Y Acad Sci 2000; 922: 1-10.
164. Kim J, Jones-Hall YL, Wei R, et al. Association between hTERT rs2736100 polymorphism and sensitivity to anti-cancer agents. Front Genet 2013; 4: 162.
165. Zou P, Gu A, Ji G, et al. The TERT rs2736100 polymorphism and cancer risk: a meta-analysis based on 25 case-control studies. BMC Cancer 2012; 12: 7.
166. Drygin D, Siddiqui-Jain A, O'Brien S, et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res 2009; 69: 7653-61.
167. Seimiya H, Muramatsu Y, Smith S, Tsuruo T. Functional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl)ation of TRF1 and telomere elongation. Mol Cell Biol 2004; 24: 1944-55.
168. Chang W, Dynek JN, Smith S. TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. Genes Dev 2003; 17: 1328-33.
169. Smith S, de Lange T. Tankyrase promotes telomere elongation in human cells. Curr Biol 2000; 10: 1299-302.
170. Kim MK, Smith S. Persistent telomere cohesion triggers a prolonged anaphase. Mol Biol Cell 2013; Epub.
171. Lu H, Lei Z, Lu Z, et al. Silencing tankyrase and telomerase promotes A549 human lung adenocarcinoma cell apoptosis and inhibits proliferation. Oncol Rep 2013; 30: 1745-52.
172. Lee MS, Yaar M, Eller MS, et al. Telomeric DNA induces p53-dependent reactive oxygen species and protects against oxidative damage. J Dermatol Sci 2009; 56: 154-62.
173. Li GZ, Eller MS, Firoozabadi R, Gilchrest BA. Evidence that exposure of the telomere 3' overhang sequence induces senescence. Proc Natl Acad Sci USA 2003; 100: 527-31.
174. Miller AO, Menozzi FD, Dubois D. Microbeads and anchorage-dependent eukaryotic cells: the beginning of a new era in biotechnology. Adv Biochem Eng Biotechnol 1989; 39: 73-95.
175. Eller MS, Li GZ, Firoozabadi R, Puri N, Gilchrest BA. Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3' overhang specific DNA. FASEB J 2003; 17: 152-62.
176. Gnanasekar M, Thirugnanam S, Zheng G, Chen A, Ramaswamy K. T-oligo induces apoptosis in advanced prostate cancer cells. Oligonucleotides 2009; 19: 287-92.
177. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 401-13.
178. Okamoto K, Bartocci C, Ouzounov I, et al. A two-step mechanism for TRF2-mediated chromosome-end protection. Nature 2013; 494: 502-5.
179. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007; 448: 1068-71.
180. Li GZ, Eller MS, Hanna K, Gilchrest BA. Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides. Exp Cell Res 2004; 301: 189-200.
181. Saretzki G, Sitte N, Merkel U, Wurm RE, von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene 1999; 18: 5148-58.
182. Gelmini S, Quattrone S, Malentacchi F, et al. Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience. Clin Chem Lab Med 2007; 45: 862-6.
183. Iwano T, Tachibana M, Reth M, Shinkai Y. Importance of TRF1 for functional telomere structure. J Biol Chem 2004; 279: 1442-8.
184. Weng D, Cunin MC, Song B, et al. Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment. Breast Cancer Res 2010; 12: R71.
185. Balasubramanian S, Neidle S. G-quadruplex nucleic acids as therapeutic targets. Curr Opin Chem Biol 2009; 13: 345-53.
186. Coleman C, Levine D, Kishore R, et al. Inhibition of melanoma angiogenesis by telomere homolog oligonucleotides. J Oncol 2010; 2010: 928628.
187. Atha DH, Miller K, Sanow AD, et al. High-throughput analysis of telomerase by capillary electrophoresis. Electrophoresis 2003; 24: 109-14.
188. NCT01273090. Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma. Available at http://clinicaltrials. gov/show/NCT01273090 [Accessed 21 December 2013].
189. NCT00310895. Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies. Available at http://clinicaltrials. gov/show/NCT00310895 Accessed on 21 December 2013.
190. NCT01836549. Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors. Available at http://clinicaltrials. gov/show/NCT01836549 [Accessed 21 December 2013].
191. Burchett KM, Ouellette MM. Inhibitors of telomerase and of poly(ADP-Ribose)polymerases synergize to limit the lifespan of pancreatic cancer cells. Apr 6-10, 2013; AACR 104th Annual Meeting, Washington, DC.
192. Vy Thi Le T, Han S, Chae J, Park HJ. G-quadruplex binding ligands: from naturally occurring to rationally designed molecules. Curr Pharm Des 2012; 18: 1948-72.
193. Pennarun G, Granotier C, Hoffschir F, et al. Role of ATM in the telomere response to the G-quadruplex ligand 360A. Nucleic Acids Res 2008; 36: 1741-54.
194. Rodriguez R, Muller S, Yeoman JA, et al. A novel small molecule that alters shelterin integrity and triggers a DNA-damage response at telomeres. J Am Chem Soc 2008; 130: 15758-9.
195. Biffi G, Tannahill D, McCafferty J, Balasubramanian S. Quantitative visualization of DNA G-quadruplex structures in human cells. Nat Chem 2013; 5: 182-6.
196. Fernando H, Rodriguez R, Balasubramanian S. Selective recognition of a DNA G-quadruplex by an engineered antibody. Biochemistry 2008; 47: 9365-71.
197. Rankin AM, Forman L, Sarkar S, Faller DV. Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells. Nucleic Acid Ther 2013; 23: 311-21.
198. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-14.
199. Lu H, Wang J, Bai Y, et al. Ionic polypeptides with unusual helical stability. Nat Commun 2011; 2: 206.
200. Uppada SB, Erickson T, Wojdyla L, et al. Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. Int J Nanomedicine 2014; 9: 43-53.